Tiv­dak gets pri­ma­ry end­point in PhI­II con­fir­ma­to­ry study

Gen­mab and Seagen’s cer­vi­cal can­cer drug Tiv­dak has reached its pri­ma­ry end­point in a con­fir­ma­to­ry Phase III tri­al, and the re­sults are ex­pect­ed to sup­port …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER